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1 Materials and Methods 
 
All reagents were obtained from commercial sources and were used without further 
purification. Sodium salt heparin from porcine intestinal mucosa with a molecular 
weight between 15,000 ± 2,000 Da (192 IU mg-1) was obtained from Calbiochem. 
Trizma hydrochloride (Tris HCl) and Human Serum were obtained from Sigma Aldrich. 
Mallard Blue (MalB) was prepared as previously described23 and stored in the dark. 
Column chromatography was performed on silica gel 60 (35-70 μm) supplied by Fluka 
Ltd. Preparative gel permeation chromatography (GPC) was performed on Biobeads 
SX-1 supplied by Bio-Rad. Thin layer chromatography was performed on Merck 
aluminium-backed plates, coated with 0.25 nm silica gel 60. 1H, 13C, 1H-1H COSY and 
1H-13C HSQC NMR were recorded on JEOL ECX400 spectrometer. ESI and HR-ESI mass 
spectra were recorded on a Bruker Daltonics Micro-TOF mass spectrometer. 
Absorbance was measured on a Shimadzu UV-2401PC spectrophotometer and 
fluorescence on a Hitachi F-4500. All experiments were performed in triplicate. For the 
purpose of calculations, the molecular weight of heparin is assumed as that of the 
sodiated analogue of a standard heparin repeat unit: namely 665.40 g mol-1, and four 
anionic charges are assumed per repeat unit. It should be noted that as supplied, 
heparin only contains ca. 30-40% of material with the active sequence of repeat units. 
However, all the sample contains anionic saccharide units which can bind to cationic 
species, even if they are in the wrong sequence. Hence to best evaluate binding 
concentrations and charge efficiencies, we report the total concentration of the anionic 
disaccharide (irrespective of whether it is present in the active form of heparin or not). 
However, all presented data which refers to the dose of binders (in mg/units) refers to 
their ability to bind only the specific clinically active heparin. 
 
2 Synthesis and Characterisation Data 
 
Compounds 1-2,18 1 3-4,31 2 5, 7,17a 3 6,32 4 8,20 5 9,21 6 11-1411 7 were synthesised using 
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Scheme S2.  Synthesis of azide-modified cholesterol 9.5,6 
1 (50 %) 2 (88 %)














Scheme S3.  Synthesis of Chol-G1. 
 
 










Scheme S5.  Synthesis of Chol-S-G1. 
 
Synthesis and Characterisation of Compound 10.  Alkyne 7 (190 mg, 0.26 mmol) was 
dissolved in dry and degassed DMF (10 mL) along with cholesterol azide 9 (120 mg, 
0.28 mmol), CuSO4·5H2O (6.5 mg, 26 μmol, 10 mol%) and sodium ascorbate (10.3 mg, 
52 μmol, 20 mol%). The reaction mixture was stirred for 72 h at room temperature. The 
DMF was then removed in vacuo at room temperature and the brown residue was 
directly purified by GPC (Biobeads SX-1, CH2Cl2) affording the desired product as a 
colourless solid (100.0 mg, 88 μmol, 37%).  1H NMR (400 MHz, CDCl3)  ppm 7.89 (br s, 
CH triazole, 0.15H), 7.80 (br s, CH triazole, 0.6H), 7.64 (br s, CH triazole, 0.15H), 7.48 (br 
s, CH triazole, 0.1H), 5.97 (br s, NH, 2H), 5.55-5.35 (m, CH2CHC, NH, 3H), 5.16 (br s, 
triazole-CH2O, 2H), 4.84 (br s, CH-Ntriazole, 1H), 4.11 (br s, CH2O, 4H), 3.28-2.95 (m, 
CH2NH, 8H), 2.56-2.37 (m, CH2N(CH3), 8H), 2.24 (br s, N(CH3), 6H), 1.97-0.5 (m, 
CH2CH2NH, C(CH3)3, CH3C(CH2O)2, CH, CH2, CH3 chol, 72H).  
13C NMR (101 MHz, CDCl3) 
14  
7  
15 (72 %)   





 ppm 173.1 (C=O), 156.2 (C=O) , 137.8 (C triazole, CH2CHC), 124.6(CH2CHC), 123.6 (CH 
triazole)(conf), 78.9 (C(CH3)3), 65.8 (CH2O), 63.0 (CH2O conf), 60.9 (CH2O conf),  58.3 
(CH2-triazole), 56.7 56.6 (CH3 CH2 CH chol), 56.2 (cholCH-triazole), 56.1, 55.3 
(CH2N(CH3)), 53.5, 50.0, 46.9, 42.9 (quat. C chol conf), 42.8 (quat. C chol conf), 42.7 
(quat. C chol conf), 42.3 (quat. C chol), 41.3 (NC(CH3)), 39.5 (CH2CH2NH), 39.5 (CH CH2 
CH3 chol), 38.8 (CH2CH2NH conf), 37.8, 37.1, 36.7, 36.2, 35.8 (CH2CH2NH), 35.4 
(CH2CH2NH conf), 32.7 (CH2CH2NH) , 31.9, 31.7, 28.4, 28.2, 28.0, 27.0, 26.7, 26.0, 24.26, 
23.9, 23.8, 22.8, 22.7, 22.6, 21.0, 20.6, 19.4, 19.3, 18.7, 17.4, 11.9 (CH3 CH2 CH chol, 
CH3 and conf).  ESI-MS: Calcd. [M+H]
+ (C61H108N9O10) m/z = 1126.8206; Obs. [M+H]
+ 
m/z = 1126.8214 (Δ = 0.7 ppm). 
 
Synthesis and Characterisation of Chol-G1.  Boc-protected compound 10 (100.0 mg, 
88 mol) was dissolved in MeOH (30 ml) and HCl gas was bubbled through the solution 
for 20 s. The reaction mixture was stirred at room temperature for 3 hours. The solvent 
was removed in vacuo to afford the product as an off-white foam (80 mg, 86 mol, 
>95%).  1H NMR (400 MHz, MeOD)  ppm 8.10-8.40 (m, CH triazole conf, 1H), 5.52 (m, 
CH=CCH2, 1H), 5.27 (s, triazole-CH2-O, 2H), 4.19 (m, CH-triazole, CCH2O 5H), 3.54-3.02 
(m, CH2NH, 16H), 2.93 (s, CH2N(CH3), 6H), 2.45-0.81 (m, 189H), 0.81-0.58 (m, 
CH2CH2NH, C(CH3)3, CH3C(CH2O)2, CH, CH2, CH3 chol, 54H).  
13C NMR (176 MHz, MeOD) 
 ppm 172.8, 157.0, 137.4, 124.3, 122.9, 78.1, 77.9, 77.7, 72.59, 65.4, 62.0, 61.5, 58.3, 
56.9, 56.7, 56.1, 56.1, 54.0, 52.9, 50.1, 50.0, 48.4, 48.1, 48.0, 47.8, 47.7, 47.6, 47.5, 
47.3, 47.2, 46.8, 45.1, 42.6, 42.4, 42.0, 39.6, 39.3, 39.2, 37.5, 37.3, 36.7, 36.6, 36.4, 
35.9, 35.9, 35.7, 34.8, 32.6, 31.7, 31.6, 31.6, 27.9, 27.7, 26.1, 24.5, 23.9, 23.8, 23.6, 
23.5, 22.1, 21.8, 21.5, 20.7, 20.3, 18.4, 18.3, 17.8, 17.8, 16.5, 11.1, 10.9.  Due to the 
existence of at least four different conformers the signal assignment for 13C was not 
possible.  ESI-MS: Calcd. [M+H]+ (C51H93N9O6) m/z = 463.8618; Obs. [M+H]
+ m/z = 
463.8619 (Δ = 0.1 ppm). 
 
Synthesis and Characterisation of Compound 15.  Alkyne 7 (175 mg, 0.24 mmol) was 
dissolved in dry and degassed DMF (10 mL) along with cholesterol azide 14 (135 mg, 
0.26 mmol), CuSO4·5H2O (5.9 mg, 24 μmol, 10 mol%) and sodium ascorbate (9.5 mg, 48 
μmol, 20 mol%). The reaction mixture was stirred for 48 h at room temperature. The 
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DMF was then removed in vacuo at room temperature and the brown residue was 
directly purified by GPC (DCM) affording the desired product as a colourless solid 
(232.0 mg, 19 μmol, 79%).  1H NMR (400 MHz, CDCl3) δ ppm 7.76 (br s, CH triazole, 
1H), 6.07 (br s, NHCO, 2H), 5.66-5.00 (m, NHCO, CH=CCH2, triazole-CH2O  6H), 4.40 (m, 
(CH2)2CHO, CH2CH2-triazole, 3H), 4.13 (br s, CCH2O, 4H), 3.04-3.00 (m, CH2NH, 10H), 
2.79-0.73 (m, CH2N(CH3), CH2N(CH3), CH, CH2, CH3 chol CH2CH2NH, 85H), 0.62 (s, CH3 
chol, 3H). 13C NMR (101 MHz, CDCl3)  ppm 193.1 (C=O), 173.1 (C=O), 156.6 (CONH), 
156.3 (CONH), 139.7 (CH=CCH2/ C triazole), 124.0 (CH triazole), 122.6 (CH2CH=CCH2) , 
79.0 (OC(CH3)3), 74.5 ((CH2)2CHO), 65.9 (CCH2O), 58.3 (triazole-CH2-O), 56.7, 56.1 
(CH,CH3 chol), 55.3, 55.5 (CH2N(CH3)), 50.0 (CH chol), 47.6 (CH2CH2-triazole), 47.0 
(CCH2O), 42.3 (C chol), 41.4 (N(CH3)), 39.7 (CH2 chol), 39.6 (CH2NH), 39.5 (CH2 chol), 
38.9 (CH2NH), 38.6 (CH2 chol), 37.6 (CH2NH), 37.0 (CH2 chol), 36.6 (C chol), 36.2, 35.8 , 
31.9, 31.9 (CH, CH2 CH3 chol), 30.6 (CH2CHNH), 28.5 (C(CH3)3), 28.2, 28.2, 28.0 (CH, CH2, 
CH3 chol), 26.8, 26.1 (CH2CHNH), 24.3, 23.8, 22.8, 22.6, 21.0, 19.3, 18.7 (CH, CH2, CH3 
chol), 17.4 (CH3CCH2O), 11.9 (CH3 chol).  ESI-MS: Calcd. [M+H]
+ (C65H116N10O12) m/z = 
614.4354; Obs. [M+H]+ m/z = 614.4382 (Δ = 4.5 ppm). 
 
Synthesis and Characterisation of Chol-S-G1.  Boc-protected compound 15 (100.0 mg, 
82 mol) was dissolved in MeOH (30 ml) and HCl gas was bubbled through the solution 
for 20 s. The reaction mixture was stirred at room temperature for 3 h. The solvent was 
removed in vacuo to afford the product as an off-white foam (85 mg, 82 mol, >95%). 
1H NMR (400 MHz, MeOD)  ppm 8.10 (s, CH triazole, 1H), 5.42-5.32 (m, CH=CCH2, 1H), 
5.23 (s, triazole-CH2-O, 2H), 4.44 (t, J = 6.8 Hz, CH2CH2-triazole , 2H), 4.39-4.26 (m, 
(CH2)2CHO, 1H), 4.16 (s, CCH2O, 4H), 3.46-3.01 (m, CH2NH, CH2N(CH3) 18H), 2.98-2.78 (s, 
CH2N(CH3), 6H), 2.40-0.79 (m, CH, CH2, CH3 chol CH2CH2NH 53H), 0.70 (s, CH3 chol, 3H). 
13C NMR (101 MHz, MeOD)  ppm 194.4 (C=O), 174.2 (C=O), 158.4 (CONH), 141.1 
(CH=CCH2/ C triazole), 127.1 (CH triazole), 123.4 (CH2CH=CCH2), 75.5 ((CH2)2CHO), 66.9 
(CCH2O), 58.8 (triazole-CH2-O), 58.0, 57.5 (CH chol), 55.5, 54.4 (CH2N(CH3)), 51.5 (CH 
chol), 49.5 (CH2CH2-triazole), 48.1 (CCH2O), 43.4 (C chol), 41.0 (CH2 chol), 40.8 (N(CH3)), 
40.6 (CH2 chol), 39.6, 38.7 (CH2NH), 38.2 (CH2 chol), 38.1 (CH2NH), 37.6 (C chol), 37.3, 
37.0, 33.1, 32.9, 31.4, 29.2, 29.2, 29.0, 25.8, 25.2, 24.9, 23.5, 23.2, 22.9, 22.1, 19.8, 




















































[M+H]+ (C55H99N10O8) m/z = 1027.7652; Obs. [M+H]
+ m/z = 1027.7642 (Δ = -0.1 ppm). 
 
3 Nile Red Assay 
 
A 2.5 mM Nile Red stock solution was made in EtOH. A binder stock solution was made 
up in PBS buffer at various concentrations depending on the starting concentration for 
the assay. Aliquots of the stock solution were taken and diluted with PBS to the desired 
concentration in a 1 ml assay volume. Nile red (1 μl) was added and the fluorescence 
emission was measured using an excitation wavelength of 550 nm. Fluorescence 
intensity was recorded at 635 nm. 
Figure S1. Fluorescence intensity of Nile Red in the presence of increasing amounts of 
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Chol-G1 and Chol-S-G1. 
 
4 Transmission Electron Microscopy 
 
Studies were performed on a FEI Technai 12 Biotwin operated at 120 kV. 10 μl of 
sample solution, in H2O was placed on a standard copper grid with Formvar and a 
carbon support film and allowed to set for three minutes. The grid was then stained 
with 1% uranyl acetate while wet, allowing the stain to run across the grid (1% in water, 
pH 4.5). The grids were allowed to rest for ten minutes before being imaged. 
 
   
Figure S2. Left: TEM image of Chol-G1 dried from aqueous solution indicating the 
formation of self-assembled micellar nanostructures. Right: TEM image of Chol-G1 in 
the presence of heparin dried from aqueous solution indicating the formation of 
self-assembled micelles that form close packed hierarchically organised nanoscale 
aggregates. 
 
5 Mallard Blue Assay 
 
In buffer.  A cuvette containing 2 mL of MalB (25 μM), heparin (27 μM) and NaCl (150 
mM) in TrisHCl (10 mM) was titrated with binder stock solution to give the cuvette a 
suitable binder-heparin charge ratio. The binder stock solution was composed of the 
100 nm 100 nm
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original MalB/heparin/NaCl/Tris HCl stock solution endowed additionally with a 
concentration of binder such that, after addition of 10 μL binder stock, the cuvette 
charge ratio (+ : –) is 0.1. After each addition, the cuvette was inverted to ensure good 
mixing and the absorbance at 615 nm was recorded against a Tris HCl (10 mM) baseline. 
A normalisation range for absorption was set against a solution of MalB (25 μM), NaCl 
(150 mM) in Tris HCl (10 mM) and one containing MalB (25 μM), heparin (27 μM), NaCl 
(150 mM) in Tris HCl (10 mM). 
 
 
Figure S3. Mallard Blue assay for Chol-G1 in buffer. 
 
Figure S4.  Mallard Blue assay for Chol-S-G1 in buffer. 
 
In serum.  Fourteen cuvettes were charged with 1.75 mL of MalB (28.53 μM) in Tris 
HCl (10 mM) and a volume of binder stock solution to give the cuvette a suitable 


















































its own MalB (25 μM), heparin (27 μM) and Tris HCl (10 mM) concentrations. The 
concentration of binder in the binder stock was determined in the same manner 
described for the heparin displacement assay in buffer. Separately, a heparin (216 μM) 
solution was made in 100% human serum. Sequentially, each cuvette was titrated with 
0.25 mL of the heparin-in-serum solution and inverted to ensure thorough mixing. The 
absorbance was recorded at 615 nm against a baseline of (1.75 mL 10 mM Tris HCl, 
0.25 mL 100% Human Serum) and a normalisation range for absorption was set against 
a solution containing exclusively MalB (25 μM) and one containing MalB (25 μM) and 
heparin (27 μM). 
 
Figure S5.  Mallard Blue assay for Chol-G1 in serum.  As the loading of heparin is 
increased, some precipitation was observed which increased the apparent absorbance, 
giving normalised values >1.0 at the end of the experiment.  This did not affect the 
determination of CE50, as no precipitation was observed at charge excesses ≤1.5.  
 
















































increased, some precipitation was observed which increased the apparent absorbance, 
giving normalised values >1.0 at the end of the experiment.  This did not affect the 
determination of the CE50, as no precipitation was observed at charge excesses ≤1.0.  
6 Isothermal Calorimetry 
 
ITC experiments were performed with a MicroCal PEAQ-ITC calorimeter (Malvern, UK) 
at 25°C. The cell volume was 208 L. All experiments were conducted by step-by-step 
injections of a constant volume of concentrated Chol-S-G1 or C22-G1 SAMul solutions 
into the calorimetric cell containing Tris HCl buffer (10 mM), or buffered solutions of 
heparin, respectively. Specifically, for CAC determination, a constant 1 L portion of 
each SAMul solutions (250 M) were injected 37 times into the reaction cell at 210 s 
intervals.  Figure S7 shows the result for CAC determination of compound Chol-S-G1 
in buffer solution as an example. The CAC is defined as the midpoint of the Q vs. C 
curve in Figures S6. For a precise determination of the midpoint of the process, first Q 
vs C data were fitted to a suitable model and then the first derivative of the Q vs C 
fitting curve was calculated (Figure S7, insert). The CAC corresponds to the minimum of 
the derivative curve, as highlighted by the arrow in the insert of Figure S7. 
 
Figure S7. Heat observed on each injection vs. final Chol-S-G1 concentration in the 
calorimetric cell. Symbols: experimental data; dotted red line: Boltzmann fit (R2=0.99). 
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Insert: The first derivative of the curve in the principal figure (in arbitrary units). The 
CAC is taken as the x-value at the minimum of dQ/dC curve (indicated by the arrow). 
 
For heparin binding, a series of SAMul solutions (4 mM) were injected in 37 portions of 
1 L at 210 s intervals, such that the concentration of Chol-S-G1 or C22-G1 was always 
above the CAC, allowing us to assume that the micelles remained intact throughout the 
experiment. The polyanion concentration in the calorimeter cell was 250 M. For the 
experiments in the presence of Human Serum Albumin (HSA), the 4 mM buffered 
solution of Chol-S-G1 or C22-G1 was preincubated for 1 h with 500 M of HSA. All 
solutions were degassed for 30 min at room temperature under stirring at 500 rpm 
prior to each experiment. After careful washing, the cell was pre-rinsed with a portion 
of the buffer or heparin solutions, respectively. On filling the cell and syringe, stirring 
was turned and each system was allowed to thermally equilibrate for 30 minutes. 
During heparin/SAMul binding experiments, when all binding sites were occupied, only 
a heat signal resulting from mixing, dilution effects and liquid friction was observed. 
The values of these unspecific heats were further confirmed by control experiments 
(data not shown); accordingly, they were subtracted from the relevant data set to yield 
the corrected integrated data of Figure 4. All experiments were run in triplicate. 
 
7 Degradation Assay 
 
The binder was dissolved (200 M) in ammonium bicarbonate (10 mM, pH=7.5). 250 
L of this binder solution was combined with 250 L of Gly-Ala standard (1 mM, in 10 
mM ammonium bicarbonate) for mass spectrometric analysis. Following incubation of 





Figure S8.  Structures of compounds and degradation products and masses of 
resulting ions.  Mass spectra of Chol-S-G1 at the start of the assay and after 
incubatuon at 25°C for 24 h and 72 h, respectively. 
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For the fluorescence degradation study the binder was dissolved in phosphate buffer 
saline (PBS, 0.01 M, endowed with NaCl (138 mM) and KCl (2.7 mM)) at a 
concentration of 25 M. In a fluorescence cuvette, an aliquot (1 mL) of this solution 
was mixed with a small amount of Nile Red (1 L, 2.5 mM in ethanol). Fluorescence 
intensity at 635 nm was recorded using 550 nm excitation wavelength. The binder 
stock solution was incubated at 25 and 37 °C for 24 h before another aliquot was taken 
for fluorescence measurements as before. In the time resolved experiment, the initial 
solution was left in the fluorimeter and the emission was monitored at regular periods 
of time at 25 °C. 
 
 
Figure S9. Fluorescence intensity of Nile Red at time 0 h and 24 h demonstrating 
degradation of Chol-S-G1 and disassembly of micelles. Incubation at 37 °C 
 
8 Computational Simulation of Micelle Stability 
 
Each SAMul monomer was parametrized according to a well-established procedure.8 
Partial charges were derived by the RESP procedure implemented in the RED server,9 
while Gaff atom types were assigned with the Antechamber10 of AmberTools18. The 
Chol-S-G1 and C22-G1 micelles were built and optimized according to our multiscale 
simulation procedure described in details in our previous work.7,11,12 Accordingly, the 































Nile Red fluorescence intensity 
at 0 h
Nile Red fluorescence intensity 
at 24 h (incubation at 37 ºC)
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Chol-S-G1, respectively; the corresponding micellar diameters were 9.3 ± 0.1 nm and 
8.7 ± 0.2 nm C22-G1 and Chol-S-G1, respectively. Each micelle was solvated with an 
appropriate number of TIP3P13 water molecules extending at least 20 Å from the solute. 
Sodium and chloride ions were added to neutralize the systems and to reach a 
physiological concentration of 0.15 M. Each system was next minimized by a 
combination of steepest descent (50000 cycles) and conjugate gradient (50000 cycles), 
followed by a heating phase of 100 ps in the constant volume-constant temperature 
(NVT) ensemble (integration step = 1fs). Then, 10 ns of system equilibration under 
isobaric-isothermal (NPT) conditions were performed (integration step = 2fs), while 
pressure was maintained by the Berendsen14 barostat. Simulations were prolonged for 
further 200 ns switching to Monte Carlo barostat implemented in Amber (2 fs time step, 
T = 25°C, P = 1 bar). Temperature was controlled by the Langevin method (damping 
coefficient of 5 ps-1) throughout all the MD simulations. Electrostatic interactions were 
computed by means of the PME algorithm. All MD simulations were carried out using 
the AMBER 1815 platform running on our CPU/GPU hybrid cluster.  Finally, 
constant-force steered molecular dynamic simulations (CF-SMD) were performed 
starting from one equilibrated micelle of each monomer (see main text for details). 
 
9 Cell Viability Assay 
 
Human hepatoblastoma cells (Hep3B, ATCC HB-8064) were cultured in Minimum 
Essential Medium (MEM) supplemented with 1 mM non-essential amino acids, 2 mM 
L-glutamine, 1 mM sodium pyruvate, 10% heat-inactivated fetal bovine serum (FBS), 
penicillin (50 U/mL) and streptomycin(50 g/mL). Cell cultures were maintained in an 
incubator (Memmert, Schwabach, Germany) at 37°C in a humidified atmosphere of 5% 
CO2/95% air (Praxair, Valencia, Spain). Cellular viability was assessed by the MTT 
[3-(4,5-dimethylthiazol-2-yl)-2,5-diprenyl tetrazolium bromide] assay, which is a 
colorimetric assay based on the ability of cells to reduce a soluble yellow tetrazolium 
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salt to blue formazan crystals. For the treatment, cells seeded in 96-well plates (15000 
cells/well) and allowed to proliferate exponentially. Two types of treatment were 
performed: i) 3 h-exposure to the chemical reagent in complete MEM without FBS, 
followed by a 21 h-recovery for which the medium was replaced with FBS-containing 
MEM and ii) 24 h-treatment in complete MEM with FBS. In both cases, MTT reagent 
(Roche Diagnostics, Mannheim, Germany) was added (20 L/well) for the last 4 h of 
the incubation period after which cells were dissolved in DMSO (100 L/well, 5 min, 37 
°C) and absorbance was detected at 570 nm using a  plate-reader spectrophotometer 



























10 NMR Spectra 
 
 



























Figure S16. 1H NMR spectrum of Chol-S-G1 in CD3OD. 
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